Could a lung fibrosis drug stop nosebleeds in HHT?
NCT ID NCT04976036
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether nintedanib, a drug already used for lung scarring, can reduce nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). About 48 adults with moderate to severe nosebleeds will take either nintedanib or a placebo twice daily for 16 weeks. The main goal is to see if the drug cuts monthly nosebleed time by at least 30% compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nintedanib
- What this could lead to
- If it works, this could provide a new treatment option to reduce the frequency and duration of nosebleeds in people with HHT.
- What could go wrong
- This is a small Phase 2 trial with only 48 participants, so results may not apply to everyone. Nintedanib can cause side effects like stomach issues, and it may not work better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TELANGIECTASIA, HEREDITARY HEMORRHAGIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Angiology Department, Lausanne University Hospital
COMPLETEDLausanne, Canton of Vaud, 1011, Switzerland
-
Clermont-Ferrand university hospital
RECRUITINGClermont-Ferrand, 63000, France
-
Lyon University Hospital, Dpt of genetics
RECRUITINGBron, 69677, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.